Search 

Helm AG is a Hamburg- based, privately owned company and represented by own subsidiaries in more

than 30 countries worldwide.

In cooperation with highly acclaimed international partners, Helm offers developments of generic

pharmaceuticals, IP researches, registrations of high quality e-CTD dossiers, launch and life cycle

management.

Our global presence and extensive variety of excellent service functions mean that Helm is your ideal

partner for all stages of the product life cycle from the initial idea generation through to the launch and

supply of the medicinal product.

We offer:

-High quality e-CTD dossiers per current EU-requirements and international registration strategies.

-Tailor made portfolio ideas.

- Excellent project management

- Collaborations for innovative technology platforms.

We are interested in:

- Identifying out-licensing and co-operation opportunities - especially for EU, Nordics, UK, LATAM, MENA

& CIS markets.

- Exploring product & brand acquisition opportunities in the targeted territories.

- Divestment of companies

We are NOT interested in:

- Regulatory Services

- CRO + CMO Services

IMI Consulting is Europe’s leading Management Consultancy and Advisory in Life Sciences having a track-record of over 27 years in servicing its clients.  Because of IMI’s 150 Associate Partner network, it provides most forms of transaction and therapeutic expertise on a worldwide basis:

Strategy Development (market intelligence, development of new ways to compete, pipeline and segment analysis, Market Access and Pricing, Strategic Plans and Planning, etc.), Transaction Support (usually as implementation of the strategy, BD&L, Mergers & Acquisitions including spin-outs ) and Capital Raising.

IMI raises capital from seed to Round C, from VCs to private investors (HNW-angels).

Its 150 Associate Partner base allows specialization in most therapeutic sectors servicing Big & Specialty Pharma, Biotech, Diagnostic, MedTech, e-health and OTC/Nutritionals:

Addiction, Analgesics, Rheumatoid Arthritis, Cancer, Cardiovascular, CNS, Dermatology, Endocrinology, Gynecology, Urology, Gastrointestinal, Hematology, Life-Cycle Management, Metabolic, Molecular Diagnostics, Respiratory, Robotics, Genetic Editing, Nutritionals, OTCs, Transplantation, etc.

We cover all of Europe, USA and Asia.

Krewel Meuselbach (KM) is a medium-sized Company of German origin. Beside the German Organisation, KM is historically strong in particular in Russia/CIS countries as well as Slovakia and Poland with own organisations.

Today KM is strategically focused on OTC-products with a strong competence in phyto-pharmaceutical drugs. Inhouse R&D and innovative pharmaceutical processing results in differentiated products with clear USP’s (e.g. free of alcohol and preservatives, standardized high bioavailability).

NATRAPHARM,  Philippines www.natrapharm.com

Organization: The total headcount is 600, among which 518 are field personnel and 82 in head office (top executives, marketing, registration, finance and HR).

NATRAPHARM Inc. is mainly focussing on antiinfectives, antibiotics, anti-asthma, anti-allergy, pediatricians. The management, the distribution and the services are common to both companies, Natrapharm Inc. and Patriot Pharmaceutical corporation. PATRIOT PHARMACEUTICAL CORPORATION handles cardiology and metabolic, neurology, psychiatry, surgery, pain management, and nephrology.

Sales performance: Natrapharm Group has one of the highest growth rate of the ethical market.

Natrapharm Group is ranking between the 10 leading pharmaceutical companies with more than 70 million US$ (combined drugstore and hospital sales less OTC) and is 2nd largest Filipino pharmaceutical company in the Ethical Segment.

Natrapharm expertise & strengths:

Long experience of partnership with multinational companies

An efficient registration department.

Own distribution.

A strong, well trained and motivated promotional force

Licensors: International companies having licensed products to Natrapharm e.g.

Sanofi-Aventis (Phils.), Abbott (Phils.), Ferrer Laboratorios (Spain), Apotex (Canada), MSD (Phils.), Stada (Germany), Samjin (Korea), Ildong (Korea)

We offer:

The organisation has been built in such a way, that NATRAPHARM has the capacity to market quickly additional products and /lines from new principals.

Products:

They have to fit inside NATRAPHARM/PATRIOT current lines and not to compete internally.

They are not necessarily new products but must be marketed in their country of origin and have an up to date registration dossier.

They can also be products already marketed in the Philippines but which is either very little or no longer promoted by the principal due to other priorities.

NATRAPHARM can either take care of a new line if the products can reach a certain level of growth or NATRAPHARM can host the line. In such case, the responsibility remains with the principal.

In any case , NATRAPHARM is looking for a long term relationship between the principal and NATRAPHARM. NATRAPHARM as 2nd largest Pilipino ethical company is open for co-marketing of innovative products from multinationals.

We are interested in:

Ethical, unique, add-on generic products (also niche products) as well as medical food with indication and clinical trials, metoprolol, clonidine, diltiazem, rosuvastatin, nicardipine inj. with CDT format dossier, climate zone IV stability.

Contact:

Dr. Thomas Högn

International Advisor and Member of the Executive Committee

Natrapharm, Inc., Philippines

Moselstrasse 5

50859 Köln

Germany

Tel.: +49 (0) 172 2910525

-        Looking for in-licensing opportunities of oncological products and

                                            related therapeutic areas such as anti-emetic products etc.

-        Solely sales and marketing of branded oncological generic products

-        only in Germany

RIEMSER Pharma GmbH is a European specialty pharmaceutical company established in December 1992 with core competencies focused niche therapy areas with high unmet medical need.

RIEMSER markets its own product portfolio in numerous therapeutic areas including oncology, neurology, anti-infectives and dermatology.

RIEMSER is present with own affiliates in Germany, France and UK and is selling its products in > 60 countries worldwide through a network of trusted partners.

We are looking to strengthen our portfolio through licensing or acquisition.